[{"id":"23608ea2-57cb-4ec4-b52e-66c473bed965","acronym":"","url":"https://clinicaltrials.gov/study/NCT04064359","created_at":"2023-08-10T18:54:54.967Z","updated_at":"2024-07-02T16:35:20.460Z","phase":"Phase 1","brief_title":"Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors","source_id_and_acronym":"NCT04064359","lead_sponsor":"Oxford BioTherapeutics Ltd","biomarkers":" LY75","pipe":" | ","alterations":" CD20 positive","tags":["LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OBT076"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-07"}]